Logo image of HBIO

HARVARD BIOSCIENCE INC (HBIO) Stock Price, Quote, News and Overview

NASDAQ:HBIO - Nasdaq - US4169061052 - Common Stock - Currency: USD

0.312  -0.02 (-5.45%)

HBIO Quote, Performance and Key Statistics

HARVARD BIOSCIENCE INC

NASDAQ:HBIO (5/6/2025, 11:33:15 AM)

0.312

-0.02 (-5.45%)

Sector
GICS SectorHealth Care
GICS IndustryLife Sciences Tools & Services
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS SubIndustryLife Sciences Tools & Services
Statistics
52 Week High3.6
52 Week Low0.32
Market Cap13.79M
Shares44.21M
Float40.68M
Yearly DividendN/A
Dividend YieldN/A
PE5.2
Fwd PE6.8
Earnings (Next)05-13 2025-05-13/bmo
IPO10-21 2013-10-21


HBIO short term performance overview.The bars show the price performance of HBIO in the last week, last 2 weeks, last month, last 3 and 6 months. 1 week 2 week 1 month 3 months 6 months -20 -40 -60 -80

HBIO long term performance overview.The bars show the price performance of HBIO in the last 1, 2 and 3 years. 1 year 2 years 3 years -20 -40 -60 -80

The current stock price of HBIO is 0.312 USD. In the past month the price decreased by -17.59%. In the past year, price decreased by -90.65%.

HARVARD BIOSCIENCE INC / HBIO Daily stock chart

HBIO Competitors/Peers

The largest stocks on the US markets in the "Life Sciences Tools & Services" sub-industry
Full List
Symbol
Company Name
TA
FA
PE
Market Cap
TMO THERMO FISHER SCIENTIFIC INC 18.94 156.61B
DHR DANAHER CORP 26.15 139.42B
A AGILENT TECHNOLOGIES INC 20.04 30.34B
IQV IQVIA HOLDINGS INC 13.63 26.77B
MTD METTLER-TOLEDO INTERNATIONAL 26.5 22.34B
WAT WATERS CORP 28.32 20.00B
WST WEST PHARMACEUTICAL SERVICES 31.38 14.97B
ILMN ILLUMINA INC 31.3 12.13B
ICLR ICON PLC 10.36 11.74B
RVTY REVVITY INC 18.55 10.99B
QGEN QIAGEN N.V. 19.39 9.26B
TEM TEMPUS AI INC N/A 9.14B

About HBIO

Company Profile

HBIO logo image Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. The company is headquartered in Holliston, Massachusetts and currently employs 330 full-time employees. The company went IPO on 2013-10-21. Its products and services are sold globally to customers ranging from renowned academic institutions and government laboratories to pharmaceutical, biotechnology and contract research organizations (CROs). Its two product categories are cellular and molecular technology (CMT) and Preclinical. The CMT product family is primarily composed of products supporting research related to molecular, cellular, organ and organoid technologies. The Preclinical product family includes products that support the preclinical research and testing phase for drug development, and in particular, testing related to data collection and analysis for safety and regulatory compliance.

Company Info

HARVARD BIOSCIENCE INC

84 October Hill Rd

Holliston MASSACHUSETTS 01746 US

CEO: James Green

Employees: 343

HBIO Company Website

HBIO Investor Relations

Phone: 15088938999

HARVARD BIOSCIENCE INC / HBIO FAQ

What is the stock price of HARVARD BIOSCIENCE INC today?

The current stock price of HBIO is 0.312 USD. The price decreased by -5.45% in the last trading session.


What is the ticker symbol for HARVARD BIOSCIENCE INC stock?

The exchange symbol of HARVARD BIOSCIENCE INC is HBIO and it is listed on the Nasdaq exchange.


On which exchange is HBIO stock listed?

HBIO stock is listed on the Nasdaq exchange.


What is the price forecast or stock price prediction for HARVARD BIOSCIENCE INC stock?

8 analysts have analysed HBIO and the average price target is 4.59 USD. This implies a price increase of 1371.15% is expected in the next year compared to the current price of 0.312. Check the HARVARD BIOSCIENCE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.


What is HARVARD BIOSCIENCE INC worth?

HARVARD BIOSCIENCE INC (HBIO) has a market capitalization of 13.79M USD. This makes HBIO a Nano Cap stock.


How many employees does HARVARD BIOSCIENCE INC have?

HARVARD BIOSCIENCE INC (HBIO) currently has 343 employees.


Is HARVARD BIOSCIENCE INC (HBIO) expected to grow?

The Revenue of HARVARD BIOSCIENCE INC (HBIO) is expected to decline by -5.55% in the next year. Check the estimates tab for more information on the HBIO EPS, Sales, EBIT and EBITDA future analyst estimates.


Should I buy HARVARD BIOSCIENCE INC (HBIO) stock?

There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:


Does HARVARD BIOSCIENCE INC (HBIO) stock pay dividends?

HBIO does not pay a dividend.


When does HARVARD BIOSCIENCE INC (HBIO) report earnings?

HARVARD BIOSCIENCE INC (HBIO) will report earnings on 2025-05-13, before the market open.


What is the Price/Earnings (PE) ratio of HARVARD BIOSCIENCE INC (HBIO)?

The PE ratio for HARVARD BIOSCIENCE INC (HBIO) is 5.2. This is based on the reported non-GAAP earnings per share of 0.06 and the current share price of 0.312 USD. Check the full fundamental report for a full analysis of the valuation metrics for HBIO.


What is the Short Interest ratio of HARVARD BIOSCIENCE INC (HBIO) stock?

The outstanding short interest for HARVARD BIOSCIENCE INC (HBIO) is 2.61% of its float. Check the ownership tab for more information on the HBIO short interest.


HBIO Technical Analysis


Chartmill TA Rating
Chartmill Setup Rating

HBIO Fundamental Analysis

ChartMill assigns a fundamental rating of 3 / 10 to HBIO. HBIO has a bad profitability rating. Also its financial health evaluation is rather negative.


Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend

HBIO Financial Highlights

Over the last trailing twelve months HBIO reported a non-GAAP Earnings per Share(EPS) of 0.06. The EPS decreased by -60% compared to the year before.


Industry RankSector Rank
PM (TTM) N/A
ROA -9.8%
ROE -19.58%
Debt/Equity 0
Chartmill High Growth Momentum
EPS Q2Q%50%
Sales Q2Q%-12.78%
EPS 1Y (TTM)-60%
Revenue 1Y (TTM)-16.14%

HBIO Ownership and Analysts

ChartMill assigns a Buy % Consensus number of 80% to HBIO. The Buy consensus is the average rating of analysts ratings from 8 analysts.

For the next year, analysts expect an EPS growth of -23.5% and a revenue growth -5.55% for HBIO


Ownership
Inst Owners82.92%
Ins Owners7.23%
Short Float %2.61%
Short Ratio2.9
Analysts
Analysts80
Price Target4.59 (1371.15%)
EPS Next Y-23.5%
Revenue Next Year-5.55%